Marin Vander Schaaf to join Eli Lilly in Visiting Scientist Fellowship in oncology

Marin Vander Schaaf has accepted a fellowship position with pharmaceutical giant Eli Lilly, joining the Visiting Scientist Fellowship program.

Lilly’s Visiting Scientist Fellowship (VSF) is a highly respected pharmaceutical industry-based program that was started in 1994. The VSF program covers multiple areas and Vander Schaaf elected to become a visiting science in Medical Affairs, in which fellows support the launch of important new medicines through cross-functional collaboration and evidence generation.

As an oncology fellow, Vander Schaaf can expect to:

• Gain exposure to oncology pipeline programs across multiple phases of development and work cross-functionally to create and execute on early phase and/or launch readiness medical affairs plans.
• Develop materials which may be utilized for disease state education, generating awareness around our science/pipeline, generating external insights and training content to be used for customer-facing roles.
• Accelerate delivery of scientific information via multichannel strategies through our internal and customer-facing channels.

She has already completed an MBA at The Citadel with MUSC’s Pharm.D./MBA concurrent degree program. She joined MUSC after completing her prepharmacy work at Washington College and has been very active as a student leader, holding offices in campus organizations including Phi Lambda Sigma, American Pharmacists Assocation, Christian Pharmacists Fellowship International, Industry Pharmacists Organization, Phi Delta Chi, Foundation for International Medical Relief of Children, and Pharmacy Student Alumni Council.

“I am honored to join Lilly, a company committed to uniting caring with discovery to create medicines that make life better for people around the world,” she posted. “I am eager to work under the leadership of Kyle Frantz, PharmD, MBA, to advance innovative therapies and make a meaningful difference in the lives of patients impacted by cancer. I can’t wait to officially join Team Lilly and help shape the future of oncology care together!”